What is the price target for EFTR stock?
8 analysts have analysed EFTR and the average price target is 11.22 USD. This implies a price increase of 6133.33% is expected in the next year compared to the current price of 0.18.
EFFECTOR THERAPEUTICS INC (EFTR) Forecast, Price Target & Analyst Ratings
NASDAQ:EFTR • US28202V2079
Current stock price
0.18 USD
-0.09 (-32.56%)
At close:
0.155 USD
-0.02 (-13.89%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EFFECTOR THERAPEUTICS INC (EFTR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 6, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$2.06
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.22
Upside
+ 6,133.33%
From current price of $0.18 to mean target of $11.22, Based on 8 analyst forecasts
Low
$10.10
Median
$11.22
High
$12.60
Price Target Revisions
1 Month
0.00%
3 Months
-51.11%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for EFTR. The average price target is 11.22 USD. This implies a price increase of 6133.33% is expected in the next year compared to the current price of 0.18.
The average price target has been revised downward by 51.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
EFTR was analyzed by 8 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about EFTR.
In the previous month the buy percentage consensus was at a similar level.
EFTR was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-24 | HC Wainwright & Co. | Initiate | Buy |
| 2023-05-26 | Stifel | Upgrade | Hold -> Buy |
| 2023-05-10 | Credit Suisse | Maintains | Outperform |
| 2023-03-09 | Credit Suisse | Maintains | Outperform |
| 2023-01-09 | JMP Securities | Maintains | Market Outperform |
| 2023-01-06 | Credit Suisse | Maintains | Outperform |
| 2022-11-17 | JMP Securities | Maintains | Market Outperform |
| 2022-08-11 | JMP Securities | Maintains | Market Outperform |
| 2022-01-25 | JMP Securities | Maintains | Market Outperform |
| 2022-01-25 | Stifel | Downgrade | Buy -> Hold |
| 2022-01-25 | Credit Suisse | Maintains | Outperform |
| 2021-11-09 | Stifel | Upgrade | Hold -> Buy |
| 2021-10-12 | Credit Suisse | Initiate | Outperform |
| 2021-10-04 | Mizuho | Initiate | Buy |
| 2021-09-21 | JMP Securities | Initiate | Market Outperform |
| 2021-09-20 | Stifel | Initiate | Hold |
| 2021-09-13 | Cantor Fitzgerald | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 6, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$2.06
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 51.52%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-16.43%
EPS (3 Months)
-20.60%
Next Earnings Summary
EFTR is expected to report earnings on 8/6/2024. The consensus EPS estimate for the next earnings is -2.06 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2024 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 42M | 1.43M -96.60% | 3.553M 148.46% | -100.00% | 76.5M | 213.18M 178.67% | 341.7M 60.29% | 433.5M 26.87% | ||||
| EBITDA YoY % growth | 15.979M 156.47% | -31.873M -299.47% | -32.35M -1.50% | -47.003M -4.28% | -66.535M -97.24% | -82.307M -23.71% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 15.819M 155.30% | -31.897M -301.64% | -32.403M -1.59% | -32.89M -4.45% | -33.471M 1.10% | -36.21M -8.18% | -62.985M -73.94% | -49.215M 21.86% | 29.529M 160.00% | 135.2M 357.85% | 242.25M 79.18% | |
| Operating Margin | 37.66% | -2,230.56% | -911.99% | N/A | N/A | N/A | N/A | -64.33% | 13.85% | 39.57% | 55.88% | |
| EPS YoY % growth | N/A | N/A | -5.83 43.55% | -15.91 -190.22% | -5.74 66.09% | -2.30 60.00% | -0.86 62.67% | -0.71 16.67% | 0.07 110.00% | 1.16 1,528.57% | 2.52 116.67% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.06 51.52% | -1.57 51.82% | -0.91 73.31% | -0.20 90.56% | -0.23 88.61% | -0.20 86.97% | -0.18 79.89% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.528M -8.57% | -8.305M -5.73% | -8.044M 6.45% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.92%
EPS Next 5 Year
14.92%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
EFFECTOR THERAPEUTICS INC / EFTR Forecast FAQ
When does EFFECTOR THERAPEUTICS INC (EFTR) report earnings?
EFFECTOR THERAPEUTICS INC (EFTR) will report earnings on 2024-08-06, after the market close.
What are the consensus estimates for EFFECTOR THERAPEUTICS INC (EFTR) next earnings?
The consensus EPS estimate for the next earnings of EFFECTOR THERAPEUTICS INC (EFTR) is -2.06 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for EFFECTOR THERAPEUTICS INC stock?
The consensus rating for EFFECTOR THERAPEUTICS INC (EFTR) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.